Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer

Table 1 Patient characteristics (n = 16)

Characteristic	n (%)	Characteristic	n (%)
Sex		Performance status
Male	5 (31)	0	7 (44)
Female	11 (69)	1	9 (57)
Age		Stage
Mean	63.25	IIIA	7 (44)
Median	61	IIIB	7 (44)
Range	49-78	III NOS	2 (13)
Race		Smoking status
White	11 (69)	Current	3 (19)
Black	2 (13)	Former	13 (81)
Other	3 (19)
Histology
Adenocarcinoma	8
Squamous Cell	6
NSCLC-NOS	2

NSCLC: Non-small cell lung cancer; NOS: Not otherwise specified.

Table 2 Adverse events

n = 16	Grade 1-2	Grade 3	Grade 4	Grade 3-4 (%)
Esophagitis	6	3	0	19
Pneumonitis	4	0	0	0
Anemia	7	1	0	6
Leukopenia	8	2	0	13
Neutropenia	4	0	0	0
Hypokalemia	3	0	1	6
Fatigue	7	1	0	6
Weight loss	2	0	0	0

Table 3 Esophagitis and pneumonitis rates in prospective trials evaluating concurrent chemoradiation in inoperable stage III non-small cell lung cancer

Ref.	Year	Design	No. of patients	Nodes	RT dose (Gy)	Chemo	Grade 3-4esophagitis	Grade 3-4pneumonitis
Furuse et al[27]	1999	Ind → RT	314	ENI	56	Cis/Vnd/Mit	3%	-
		CCRT			561		2%	1%
Zatloukal et al[28]	2004	Ind → RT	102	ENI	60	Cis/Vno	4%
		CCRT					18%	4%
Fournel et al[26]	2005	Ind → RT	205	ENI	66	Cis/Vno	2%
		CCRT → Cons				Cis/Eto → Cis/Vno	32%	5%
Belani et al[4]	2005	Ind → RT	257	IFRT	63	Cbp/Pac	-	-
		Ind → CCRT					19%	4%
		CCRT → Cons					28%	16%
Vokes et al[2]	2007	CCRT	366	ENI	66	Cbp/Pac	28%	4%
		Ind → CCRT					30%	10%
Belderbos et al[25]	2007	Ind → RT	158	ENI	662	Cis/Gem	5%
		CRT				Cis	14%	18%
Socinski et al[41]	2008	Ind → CCRT	69	“ENI discouraged but allowed”	74	Cbp/Pac	16%	16%
		Ind → CRT				Cbp/Gem	39%	37%
Blumenschein et al[23]	2011	CCRT	87	“Selective nodal irradiation”	63	Cbp/Pac/	8%	22%
						Cet
Curran et al[42]	2011	Ind → RT	407	ENI	63	Cis/Vnb	4%	-
		CCRT			63	Cis/Vnb	22%	13%
		CCRT			69.63	Cis/Eto	45%	15%
Hoang et al[5]	2012	CCRT	546	IFRT	60	Cbp/Pac	< 1%	1%
		CCRT + Thl				Cbp/Pac/Thl	< 1%	1%

¹Split course;

²2.75 Gy/d;

³BID (twice daily). Cis: Cisplatin; Vnd: Vindesine; Mit: Mitomycin; Vno: Vinorelbine; Eto: Etoposide; Cbp: Carboplatin; Pac: Paclitaxel; Gem: Gemcitabine; Cet: Cetuximab; Vnb: Vinblastine; Thl: Thalidomide; Doc: Docetaxel; Ind: Induction chemotherapy; RT: Radiation therapy; CCRT: Concurrent chemoradiotherpy; Cons: Consolidation; ENI: Elective nodal irradiation; IFRT: Involved field radiation therapy; NSCLC: Non-small cell lung cancer.

Table 4 Myelosuppression rates from prospective trials evaluating concurrent chemoradiation in inoperable non-small cell lung cancer

Ref.	Year	Design	No. of patients	Chemo	Grade 3-4
					Anemia	Leukopenia	Neutropenia
Belani et al[4]	2005	CCRT → Cons	92	Cbp/Pac	10%	51%	26%
Vokes et al[2]	2007	CCRT	184	Cbp/Pac	5%	36%	15%
Hoang et al[5]	2012	CCRT	275	Cbp/Pac	3%	23%	51%
Blumenschein et al[23]	2011	CCRT	87	Cbp/Pac/Cet	“Blood/bone marrow”: 48%

Cbp: Carbo; Pac: Paclitaxel; Cet: Cetuximab; CCRT: Concurrent chemoradiotherpy; Cons: Consolidation.